US · RYTM · BIOTECHNOLOGY
Rhythm Pharmaceuticals, Inc. (RYTM) intrinsic value and stock valuation
$112.36as of 2026-11-21 · Mkt cap 7.59B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Rhythm Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values RYTM with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from RYTM’s statements →
Rhythm Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Revolution Medicines, Inc. (RVMD) $161.20
- Protagonist Therapeutics, Inc. (PTGX) $121.40
- Kiniksa Pharmaceuticals International, plc (KNSA) $93.90
- Relay Therapeutics, Inc. (RLAY) $16.12
- uniQure N.V. (QURE) $19.35
- Stoke Therapeutics, Inc. (STOK) $26.81
- Viridian Therapeutics, Inc. (VRDN) $29.96
- Syndax Pharmaceuticals, Inc. (SNDX) $8.72
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.15M |
| Operating income | -$-192.02M | -$-265.5M | -$-184.36M | -$-179.16M | -$-170.06M |
| Net income | -$-196.54M | -$-260.6M | -$-184.68M | -$-181.12M | -$-69.61M |
| EPSd | -$-3.02M | -$-4.27M | -$-3.2M | -$-3.48M | -$-1.4M |
| Operating cash flow | -$-115.67M | -$-113.88M | -$-136.16M | -$-173.43M | -$-146M |
| Capital expenditure | -$-950K | $0.00 | -$-50K | -$-4.28M | -$-5.43M |
| Free cash flow | -$-116.63M | -$-113.88M | -$-136.2M | -$-177.71M | -$-151.44M |
| Total assets | $480.2M | $392.3M | $332.8M | $382.5M | $329.5M |
| Total debt | $3.99M | $3.94M | $1.26M | $1.94M | $2.55M |
| Net debt | -$-50.31M | -$-85.2M | -$-58.82M | -$-125.73M | -$-56.7M |
| Total equity | $270M | $164.6M | $169.8M | $264.3M | $284.2M |
| Cash and short-term investments | $389M | $320.6M | $275.9M | $333.3M | $294.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.15M |
| Cost of revenue | $19.5M | $13.4M | $9.3M | $2.13M | $600K |
| Gross profit | $170.3M | $116.8M | $68.1M | $21.5M | $2.56M |
| Research and development expenses | $167.3M | $238M | $135M | $108.6M | $104.1M |
| Selling, general and administrative expenses | $194.9M | $144.3M | $117.5M | $92M | $68.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $362.3M | $382.3M | $252.5M | $200.7M | $172.6M |
| Cost and expenses | $381.8M | $395.6M | $261.8M | $202.8M | $173.2M |
| Interest income | $15.3M | $14.7M | $14M | $4.03M | $450K |
| Interest expense | $20.6M | $20.6M | $13.9M | $5.2M | $0.00 |
| Depreciation and amortization | $1.34M | $1.56M | $1.76M | $1.67M | $1.16M |
| Ebitda | -$-174.12M | -$-238.09M | -$-168.46M | -$-174.25M | -$-68.45M |
| Operating income | -$-192.02M | -$-265.5M | -$-184.36M | -$-179.16M | -$-170.06M |
| Total other income/expenses, net | -$-4.03M | $5.25M | $240K | -$-1.96M | $100.5M |
| Income before tax | -$-196.04M | -$-260.26M | -$-184.11M | -$-181.12M | -$-69.61M |
| Income tax expense | $500K | $350K | $560K | $0.00 | $0.00 |
| Net income | -$-196.54M | -$-260.6M | -$-184.68M | -$-181.12M | -$-69.61M |
| Weighted average shares outstanding | $65M | $61M | $57.7M | $52.1M | $49.6M |
| Weighted average diluted shares outstanding | $65M | $61M | $57.7M | $52.1M | $49.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $389M | $320.6M | $275.9M | $333.3M | $294.9M |
| Net receivables | $26.1M | $18.5M | $14.9M | $6.22M | $1.02M |
| Inventory | $25.8M | $18.7M | $8.62M | $2.92M | $110K |
| Total current assets | $466.9M | $374.2M | $308.3M | $354.2M | $308.4M |
| Property, plant and equipment, net | $4.15M | $4.11M | $2.12M | $3.38M | $4.33M |
| Goodwill and intangible assets | $5.32M | $6.17M | $7.03M | $7.88M | $4.66M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $13.3M | $18.1M | $24.5M | $28.3M | $21.1M |
| Total assets | $480.2M | $392.3M | $332.8M | $382.5M | $329.5M |
| Accounts payable | $14M | $12.3M | $4.88M | $4.8M | $5.74M |
| Short-term debt | $650K | $0.00 | $770K | $680K | $610K |
| Deferred revenue | $190K | $1.29M | $1.29M | $1.43M | $7M |
| Total current liabilities | $105.9M | $115.5M | $55.2M | $39.8M | $43.4M |
| Long-term debt | $3.34M | $3.94M | $490K | $1.26M | $1.95M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $104.2M | $112.2M | $107.8M | $78.4M | $1.95M |
| Capital lease obligations | $3.99M | $3.94M | $1.26M | $1.94M | $2.55M |
| Total liabilities | $210.2M | $227.7M | $163M | $118.2M | $45.4M |
| Common stock | $70K | $60K | $60K | $60K | $50K |
| Retained earnings | -$-1.35B | -$-1.16B | -$-894.74M | -$-710.06M | -$-528.94M |
| Accumulated other comprehensive income (loss) | -$-800K | -$-40K | $130K | -$-90K | -$0.00 |
| Total equity | $270M | $164.6M | $169.8M | $264.3M | $284.2M |
| Total investments | $334.7M | $231.4M | $215.8M | $205.6M | $235.6M |
| Total debt | $3.99M | $3.94M | $1.26M | $1.94M | $2.55M |
| Net debt | -$-50.31M | -$-85.2M | -$-58.82M | -$-125.73M | -$-56.7M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-196.54M | -$-260.6M | -$-184.68M | -$-181.12M | -$-69.61M |
| Depreciation and amortization | $1.34M | $1.56M | $1.76M | $1.67M | $1.16M |
| Stock-based compensation | $66.8M | $39.7M | $32.6M | $19.8M | $20.8M |
| Change in working capital | -$-970K | $10.6M | $4.81M | -$-19.72M | $1.9M |
| Accounts receivable | -$-7.57M | -$-3.65M | -$-8.64M | -$-5.2M | -$-1.25M |
| Inventory | -$-7.47M | -$-10.12M | -$-5.71M | -$-2.81M | -$-10K |
| Accounts payable | $21.9M | $21.9M | $14.8M | $1.54M | $18.3M |
| Net cash provided by operating activities | -$-115.67M | -$-113.88M | -$-136.16M | -$-173.43M | -$-146M |
| Investments in property, plant and equipment | -$-950K | $0.00 | -$-50K | -$-4.28M | -$-5.43M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $4M | $100M |
| Net cash used for investing activities | -$-137.15M | -$-48.17M | -$-5.67M | $28M | -$-62.16M |
| Common stock issued | $237.9M | $195.2M | $48.9M | $131.1M | $161.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | -$-3.97M | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $218M | $191.2M | $74.4M | $213.8M | $166.5M |
| Net change in cash | -$-34.78M | $29.2M | -$-67.6M | $68.4M | -$-41.68M |
| Cash at end of period | $54.8M | $89.6M | $60.4M | $128M | $59.6M |
| Operating cash flow | -$-115.67M | -$-113.88M | -$-136.16M | -$-173.43M | -$-146M |
| Capital expenditure | -$-950K | $0.00 | -$-50K | -$-4.28M | -$-5.43M |
| Free cash flow | -$-116.63M | -$-113.88M | -$-136.2M | -$-177.71M | -$-151.44M |
Line items
Line items
Line items
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
- CEO
- David Meeker
- Employees
- 414
- Beta
- 1.88
Explore
Frequently asked questions
What is the intrinsic value of Rhythm Pharmaceuticals, Inc. (RYTM)?
Rhythm Pharmaceuticals, Inc. (RYTM) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is RYTM undervalued?
RYTM trades at a price of $112.36 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.